Penn C12-2aN Lipid Improves mRNA Vaccine Efficacy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Pennsylvania researchers altered the ionizable lipid of LNPs by adding imidoester cross‑linkers, creating the C12‑2aN formulation.
- C12‑2aN LNPs boosted glycolysis gene expression and lactate production in human dendritic cells and mouse models.
- C12‑2aN LNPs delivered more than three times as much mRNA to lymph nodes relative to the liver compared with an FDA‑approved formulation.
- C12‑2aN LNPs lowered systemic inflammation gene expression and reduced blood inflammatory markers in mice, leading to smaller temperature rises after vaccination.
- C12‑2aN LNPs achieved vaccine efficacy on par with FDA‑approved lipids in a mouse model of mRNA‑based COVID‑19 vaccination.
Why it matters: The C12‑2aN lipid gives vaccine developers a tool to amplify immune response without the usual fever‑and‑fatigue side effects, potentially improving patient acceptance and expanding the therapeutic reach of mRNA platforms to diseases beyond COVID‑19. By targeting lymph nodes more efficiently, the formulation also reduces off‑target liver accumulation, lowering systemic exposure and making vaccines safer for broader populations.
